Monsenso applies for inclusion on Nasdaq First North Growth Market Denmark

Monsenso applies for inclusion on Nasdaq First North Growth Market Denmark

May 11, 2020

Copenhagen, Denmark – 11 May  2020 – Monsenso has published today a company description detailing the company’s share offer and its plans to trade on Nasdaq First North Growth Market Denmark.

Monsenso’s mobile health solution for mental health is going public, and private Danish investors are invited to participate in Monsenso’s global expansion.

With a scalable and highly sought-after solution within mobile healthcare, Danish company Monsenso has managed to deliver growth in revenue, increase the number of customers, and deliver profits. Now the success must continue globally, which is why Monsenso decided to list on Nasdaq First North Growth Market Denmark. This will allow Danish private investors to join Monsenso’s global expansion of a clinically validated and certified mobile health solution.

The Monsenso mHealth solution has improved the treatment and quality of life for thousands of people affected by mental illness. It has estimated that the number of potential users in Europe alone, is 125 million people, who are affected by mental illness every year. The solution hits a market for mobile healthcare solutions, which is expected to increase on average 40% per year during the upcoming years.

Thomas Lethenborg, CEO of Monsenso, says:

“Our decision to go public has brought positive response both from customers, potential investors, and from the entire team, who has worked hard to get here. I am particularly pleased with the support; we have received from the 40 investors who have made prior commitments to buy shares. This includes Monsenso’s management, the board and employees, who have decided to be co-investors on the journey that we are now beginning.

We have succeeded in establishing ourselves as a strong player in new exciting markets, and now we can develop the company further for the benefit of our users, customers, employees, as well as our shareholders.

The planned IPO is an important milestone in Monsenso’s development. The IPO gives the company a stronger foundation for the continued development of its solution as well as a stronger sales and support set-up. It  strengthens Monsenso’s potential to grow in mHealth market, which is expected to grow significantly during the upcoming years”.

The Company Description, the brochure, as well as further information is available for Denmark-based investors on  www.monsenso.com/investors and potential investors can register for one of the virtual investor meetings on www.monsenso.com/ipo.

For more information:

Monsenso
CEO Thomas Lethenborg
Tel: +45  21 29 88 27
E-mail: Lethenborg@monsenso.com

Monsenso is ready for the stock exchange, after continuous growth for several years

Monsenso is ready for the stock exchange, after continuous growth for several years

Apr 28, 2020

Copenhagen, Denmark – 28 April  2020 – Danish start-up Monsenso is ready for the stock exchange after continuous growth for several years, with its easily scalable and highly demanded mobile health solution for mental healthcare. The Danish start-up Monsenso has managed to deliver growth in revenue, increase its number of customers, and deliver profits.

Monsenso will now leverage this momentum and invite Danish investors on its upcoming global growth journey.

With a certified and scalable mobile health solution, Monsenso’s technology has proven to be a useful tool to achieve better mental health for more people, with significantly lower costs to society as a result.

The demand for the Monsenso mHealth solution is high, and at the same time, the competitive situation is exceptionally favourable. The Monsenso solution is clinically validated, and thus, it differs significantly from the many stand-alone apps that are available online.

Today, the Monsenso mHealth solution has been deployed to 10 different countries. Now, it has the opportunity to scale up further to more markets, as satisfied customers increase their orders, and new customers sign up.

Growth Plan

Monsenso expects to double its revenue in the coming financial year from DKK 9 million in 2020 to DKK 18.5 million in 2021, and accomplish a revenue of DKK 75 million by 2024.

With the IPO, Monsenso aims to raise a total of DKK 20 million to finance the company’s continued growth journey, expand the organization, and be able to scale up the business further in line with growing demand.

Monsenso has chosen to be admitted to trading at NASDAQ First North GM Copenhagen because broader ownership, as well as the transparency and responsibility that the acquisition entails, will make Monsenso a more attractive partner for its customers.

Corona crisis increases the need for the Monsenso mHealth solution

The current global corona crisis is increasing the demand for Monsenso’s mHealth solution because the technology provides an effective solution to the problems faced due to the isolation experienced by hundreds of thousands of people around the world.

The crisis and the accompanying quarantine measures are spurring people to embrace mobile solutions even more. Digitalization has taken a massive leap in a very short time, and mHealth solutions and well as telemedicine portals will be in high-demand.

Monsenso presents this Intention to Float, paving the way for a listing on NASDAQ First North GM in Copenhagen before summer. Monsenso’s management looks forward to this milestone for the company.

CEO Thomas Lethenborg: “Monsenso’s mHealth solution is hitting a huge and unmet global need to help treat mental disorders. With our strong research foundation and a demonstrated proof of business for private and public players, we believe that the time is right to raise funds and continue our global expansion.”

Chairman Jukka Pertola: “The corona crisis is clearly showing that mobile health solutions work well and that there is a great need in the market. When, during a crisis like corona, physical contact is not possible, mobile health solutions like Monsenso’s are needed even more. That’s why we stick to our plans for a stock exchange listing. “

CTO Jakob Bardram: “Monsenso offers clinicians an easy-to-use tool to monitor patients remotely. With continuous real-time feedback of data, treatment can be tailored for each patient; this results in a more optimal treatment at a lower cost. In the next phase, we will make the solution more scalable and increase the content of the treatment to meet increasing demand.”

Partnerships

Monsenso has entered into a long-term partnership with one of the world’s leading global pharmaceutical companies to use Monsenso’s healthcare solution to support product launches in select countries in Europe.

Monsenso also collaborates with several customers in Denmark and the UK, including the Capital Region, a number of Danish municipalities, and Exeter University.

In the coming years, Monsenso wants to expand and strengthen its market position, and constantly invest in making the solution more configurable with new treatment options, in order to meet the growing demand from more mental disorders.

For information on how to purchase stock options visit www.monsenso.com/investors/

For additional information contact:

Jennifer Highland
Marketing, Monsenso
marketing@monsenso.com

University of Exeter partners with mHealth provider Monsenso in dementia research project.

University of Exeter partners with mHealth provider Monsenso in dementia research project.

Mar 25, 2019

Copenhagen, Denmark – 25 March 2019. The University of Exeter, supported by the South West Academic Health Science Network, has partnered with Danish mobile health provider Monsenso in ‘The MOVE Study’ (formerly known as The Klick Project), a research project that aims to review how the Monsenso Solution can be used to support individuals to engage in healthy behaviours that could make a difference to their risk of getting dementia. The Monsenso Solution is a mobile platform, where the individual is prompted with daily self-assessments, weekly clinical scales, while sensor data is collected via the phone. Moreover, it connects the individual and clinician, visualising individual-reported data for both parties and facilitates the possibility of providing patients with relevant information to handle specific challenges that may impact their wellbeing.

Both from a societal and a clinical standpoint, the burden of dementia is a growing challenge. The number of people affected by dementia worldwide will reach 75 million people in 2030. In the UK, for example, Dementia UK estimated that approximately 850,000 people were living with dementia[1]. In addition, it was estimated that one in three people born in 2015 will develop dementia in their lifetime[2]. Therefore, new ways of tackling this challenge must be found.

In collaboration with Monsenso, the lead researchers on The MOVE Study – Dr Barbora Silarova and Dr Rachel Collins will set up the solution to support The MOVE Study, and hereafter demonstrate its capabilities for clinicians and patients and receive their feedback. The findings will be used to guide development of future intervention that focuses on changing healthy behaviours that could make a difference to people’s risk of getting dementia. It is planned for the intervention to be delivered in primary care. The configuration of the Monsenso Solution for The MOVE Study will include one of the newest additions to the system; an integration to Withings (wearable technology) which allows for collection of sensor data, such as physical activity, sleep and pulse.

Thomas Lethenborg, CEO of Monsenso, says: “Dementia is a huge challenge for society to overcome, and it will be growing in the coming years due to an ageing population. We are looking forward to testing whether our solution can help people to engage in healthy behaviours to live a healthy life. We may draw on experiences gained from the H2020 funded WellCo project, which aims at improving the well-being of elderly people.”

About University of Exeter

University of Exeter combines teaching excellence and high levels of student satisfaction with world class research at their campuses in Devon and Cornwall. They are part of the Russell Group as one of the 24 leading UK universities. Their success is built on a strong partnership with their students and a clear focus on high performance.

For more information about dementia research conducted at University of Exeter, please see http://www.exeter.ac.uk/dementia/.

About South West Academic Health Science Network

The South West Academic Health Science Network (SW AHSN) works to improve the health and patient experience of people in the South West by supporting and accelerating innovation and quality improvement. SW AHSN is part of a national network of 15 AHSNs set up by NHS England, to identify, adopt and disseminate innovative healthcare. As part of KLICK, they will be aiding in the conversation and co-design of solutions to better meet patient needs by bringing together innovators and adopters of new ideas for health and social care.

To learn more, visit https://www.swahsn.com/.

About Monsenso

Monsenso is an innovative technology company offering a mHealth solution that optimises the treatment of mental disorders. The smartphone-based solution gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data, and it connects individuals, carers and health care providers enabling personalised treatment, remote care and early intervention.

To learn more, visit www.monsenso.com

For more information about Monsenso contact:

Thomas Lethenborg
CEO
Monsenso 
+45 21298827
lethenborg@monsenso.com

[1] Dowrick, A., Southern, A. . Dementia 2014: Opportunity for change. 2014  17/10/2018]; Available from: https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_2014_opportunity_for_change.pdf.

[2] Lee, V.S., J. Simpson, and K. Froggatt, A narrative exploration of older people’s transitions into residential care. Aging Ment Health, 2013. 17(1): p. 48-56.

Leading Danish addiction treatment center, KABS, enhances treatment services with data-driven mobile health technology

Leading Danish addiction treatment center, KABS, enhances treatment services with data-driven mobile health technology

Jan 30, 2019

Copenhagen, Denmark – 30 January 2019. The management of Copenhagen-based KABS acknowledges that there is a need to digitise parts of the treatment to both ease the burden of difficult and time consuming data collection and to offer people better, more proactive and personalised treatment. Therefore, Monsenso and KABS have joined forces to provide more effective, user-centered treatment by using mobile health technology to better support people struggling with addiction.

“Knowing about the individual’s well-being is crucial for setting up the best possible treatment. Gathering data solely through face-to-face interviews might often be inaccurate and time consuming, and the data may be biased by the individuals’ well-being and motivations during each interview session. We have decided to use the Monsenso solution, to improve our data collection using a digital platform for individuals to do self-assessments. By knowing more about the individuals, we are able to provide better treatment, while it is also an attempt to reach and attract the young people, who are in need of help.” says Rasmus Axelsson, Head of KABS.

The Monsenso solution will be implemented in a pilot project in the unit KABS Stjernevang with 10 therapists using the system. The pilot project includes both alcohol and substance abuse, as well as cases of comorbidity, where individuals also suffer from a mental illness. The mHealth solution combines data collection through self-assessments and questionnaires to provide the therapists with a detailed longitudinal view of the person’s wellbeing.

The Monsenso solution will be customised to complement KABS’ services in order to provide therapists with an overview of the individual’s illness progression, their symptoms and any medication compliance. The solution also notifies therapists and users when they display any illness related warning signs, enabling them to monitor each user remotely and to intervene at an early stage.

“We are looking forward to be working with KABS and the experienced team of therapists. We understand the very close relationship between mental health and addiction and are working closely with Rasmus and his Team to enhance the way alcohol and substance abuse treatment is delivered.” said Thomas Lethenborg, CEO of Monsenso.

Click here to read the press release in Danish.

About KABS

KABS is part of Glostrup Municipality and is one of the largest addiction treatment centers in Denmark, and has provided medical treatment and therapy for substance and alcohol abuse for many years. The organisation currently provides medical and social treatment for substance and alcohol abuse to approximately 800 citizens from 46 municipalities.

To learn more, visit https://www.kabs.dk/

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For more information about Monsenso contact:

Thomas Lethenborg
CEO
Monsenso
+45 21298827
lethenborg@monsenso.com

Municipality of Ikast-Brande strengthens its addiction services with Monsenso

Municipality of Ikast-Brande strengthens its addiction services with Monsenso

Jan 16, 2019

Copenhagen, Denmark – 17 January 2019. Monsenso, a Danish healthtech company focused on mobile health solutions for mental health, is proud to announce our newest collaboration with the Center for Rusmiddelbehandling in the municipality of Ikast-Brande. The aim of the pilot project is to examine how the Monsenso mhealth solution can be used as an integrated part of the addiction treatment, across both alcohol and substance misuse.

The project, which will be running from January 2019 to January 2020, will primarily involve people in outpatient treatment. This is the first step in implementing the solution more broadly throughout the center’s services, widening the scope and population that they can reach, and ultimately benefitting the people living in the municipality.

The aim of the project is to evaluate the clinical and financial benefits of using the Monsenso Solution. This is relevant for clients currently receiving treatment and for clients who have completed their treatment and are part of the post-treatment service, where it is crucial not to fall back into old and undesired habits.

With the help of the Monsenso solution and the data that are being reported directly by the client, the clinician will be able to personalise the treatment to fit each client’s needs, as they have knowledge of the client’s issues over time. It also allows for clinicians to be more proactive and reach out to clients at the time they need help in order to avoid potential relapses.

Thomas Lethenborg, CEO of Monsenso ApS, says: “The Center for Rusmiddelbehandling in Ikast-Brande strives to enhance the quality of their services by implementing the newest technology. Addiction services are an interesting growth area for Monsenso, and we are convinced that implementing our solution will be beneficial to both clients and clinicians. Moreover, the collected data are opening up a number of exciting and innovative opportunities relating to addiction treatment.”

Mette Christensen, the Head of the Center for Rusmiddelbehandling, says: “We are implementing this new technology in our addiction services to improve the quality of the treatment we can provide. At the same time, we get to be more pro-active and understand our clients better, which will profit both them and the entire municipality. The clinicians are motivated to try a different working method, so we look forward to getting started”.

Click here to read the press release in Danish.


About Center for Rusmiddelbehandling
Center for Rusmiddelbehandling (CFR) is Ikast-Brande municipality’s offer of counselling, treatment and prevention of alcohol and substance misuse. The center currently has 20 employees with different educational backgrounds, which provides a wide range of competences. CFR offers both outpatient alcohol and substance treatment, day treatment and substitution therapy.
For more information visit www.cfr.ikast-brande.dk.

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For further information about Monsenso contact:
Thomas Lethenborg
CEO
Monsenso
+45 21298827
Lethenborg@monsenso.com

Monsenso partnered with University of Cambridge to support research into individuals with intellectual disabilities

Monsenso partnered with University of Cambridge to support research into individuals with intellectual disabilities

Oct 24, 2018

Monsenso has partnered with the University of Cambridge, Department of Psychiatry, to support the research of using mHealth to help identify the possible causes of behavioural problems for those with intellectual disabilities.

The University plans to further their research and advance their understanding of behavioural problems in individuals with intellectual disabilities, which will initially include a  group of people with Prader-Willi Syndrome. The study will be focusing on recording of information & data relating to their mental health state and try to elucidate the reasons for the behavioural problems.

Professor Tony Holland, Chair in Learning Disabilities in the Department of Psychiatry at the University of Cambridge said: “In the field of learning disabilities, we are asking questions like: “How do we detect poor mental health and behavioural problems early on?” By applying new technological solutions, such as Monsenso, we can not only improve how we collect data, but also how we can identify signatures that are an indication of poor mental health and behavioural problems.”

The Monsenso mHealth solution is used in a growing number of mental health innovation and research related studies. Monsenso is delighted to be working with Prof. Holland and team. The solution will be employed to monitor individuals and collect behavioural and physiological data via the smartphone delivered solution. The solution will collect daily self-assessment data, diary entries and record physiological measures, complemented by passive data collection by both the smartphone and wearable devices. This aim of the study is to use this data to determine the effectiveness of treatment on a number of physiological measures, and to compare physiological measures between groups of participants. Additionally, this study also wishes to see if this data can potentially identify triggers, or causes, of the behavioural problems of participants.

In previous similar research studies, clinicians, nurses and researchers were also asked to collect data about the client’s mental state and outbursts. However, this data was pen-and-paper based, which was clearly vulnerable to inaccuracies, as it was dependent upon the nurse’s ability to remember and record the events as soon as they occurred. It was also difficult for these notes to provide a longitudinal picture of the client’s behaviour over time. Applience of the technological solutions is a massive advancement in how researchers utilise and collect research data in this complex setting.

“Research is essential to find out which treatment and interventions work better for the patients and our mHealth solution can be used to enhance data collection and outcome measures that support this. Using this technology, Monsenso can help provide a detailed longitudinal overview about the individual’s mental state, which can help to identify signatures of behavioural patterns, and even forecast future conditions. We are proud to support the researchers of the University of Cambridge”, says Thomas Lethenborg, CEO of Monsenso.